Armitage JO, Longo DL (2022) Mantle-cell lymphoma. N Engl J Med 386(26):2495–2506. https://doi.org/10.1056/NEJMra2202672

Article  CAS  PubMed  Google Scholar 

Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR (2016) 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin 66(6):443–459. https://doi.org/10.3322/caac.21357

Article  PubMed  Google Scholar 

Herrmann A, Hoster E, Zwingers T, Brittinger G, Engelhard M, Meusers P, Reiser M, Forstpointner R, Metzner B, Peter N, Wormann B, Trumper L, Pfreundschuh M, Einsele H, Hiddemann W, Unterhalt M, Dreyling M (2009) Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 27(4):511–518. https://doi.org/10.1200/JCO.2008.16.8435

Article  PubMed  Google Scholar 

Campo E, Rule S (2015) Mantle cell lymphoma: evolving management strategies. Blood 125(1):48–55. https://doi.org/10.1182/blood-2014-05-521898

Article  CAS  PubMed  Google Scholar 

Epperla N, Hamadani M, Fenske TS, Costa LJ (2018) Incidence and survival trends in mantle cell lymphoma. Br J Haematol 181(5):703–706. https://doi.org/10.1111/bjh.14699

Article  PubMed  Google Scholar 

Abrahamsson A, Albertsson-Lindblad A, Brown PN, Baumgartner-Wennerholm S, Pedersen LM, D’Amore F, Nilsson-Ehle H, Jensen P, Pedersen M, Geisler CH, Jerkeman M (2014) Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study. Blood 124(8):1288–1295. https://doi.org/10.1182/blood-2014-03-559930

Article  CAS  PubMed  Google Scholar 

Ryan CE, Armand P, LaCasce AS (2024) Frontline treatment of mantle cell lymphoma. Blood. https://doi.org/10.1182/blood.2023022352

Article  PubMed  Google Scholar 

Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC, Pfreundschuh M, Reiser M, Metzner B, Einsele H, Peter N, Jung W, Wormann B, Ludwig WD, Duhrsen U, Eimermacher H, Wandt H, Hasford J, Hiddemann W, Unterhalt M (2008) A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 111(2):558–565. https://doi.org/10.1182/blood-2007-06-095331

Article  CAS  PubMed  Google Scholar 

Rampotas A, Wilson MR, Lomas O, Denny N, Leary H, Ferguson G, McKay P, Ebsworth T, Miller J, Shah N, Martinez-Calle N, Bishton M, Everden A, Tucker D, El-Hassad E, Hennessy B, Doherty D, Prideaux S, Faryal R, Hayat A, Keohane C, Marr H, Gibb A, Pocock R, Lambert J, Lacey R, Elmusharaf N, Clifford R, Eyre TA (2021) Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: A UK and Ireland analysis. Br J Haematol 194(2):365–377. https://doi.org/10.1111/bjh.17513

Article  CAS  PubMed  Google Scholar 

Hoster E, Rosenwald A, Berger F, Bernd HW, Hartmann S, Loddenkemper C, Barth TF, Brousse N, Pileri S, Rymkiewicz G, Kodet R, Stilgenbauer S, Forstpointner R, Thieblemont C, Hallek M, Coiffier B, Vehling-Kaiser U, Bouabdallah R, Kanz L, Pfreundschuh M, Schmidt C, Ribrag V, Hiddemann W, Unterhalt M, Kluin-Nelemans JC, Hermine O, Dreyling MH, Klapper W (2016) Prognostic value of Ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the european mantle cell lymphoma network. J Clin Oncol 34(12):1386–1394. https://doi.org/10.1200/JCO.2015.63.8387

Article  CAS  PubMed  Google Scholar 

Cheah CY, Seymour JF, Wang ML (2016) Mantle cell lymphoma. J Clin Oncol 34(11):1256–1269. https://doi.org/10.1200/JCO.2015.63.5904

Article  CAS  PubMed  Google Scholar 

Visco C, Chiappella A, Nassi L, Patti C, Ferrero S, Barbero D, Evangelista A, Spina M, Molinari A, Rigacci L, Tani M, Rocco AD, Pinotti G, Fabbri A, Zambello R, Finotto S, Gotti M, Carella AM, Salvi F, Pileri SA, Ladetto M, Ciccone G, Gaidano G, Ruggeri M, Martelli M, Vitolo U (2017) Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi. Lancet Haematol 4(1):e15–e23. https://doi.org/10.1016/S2352-3026(16)30185-5

Article  PubMed  Google Scholar 

Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Geisler CH, Trneny M, Stilgenbauer S, Kaiser F, Doorduijn JK, Salles G, Szymczyk M, Tilly H, Kanz L, Schmidt C, Feugier P, Thieblemont C, Zijlstra JM, Ribrag V, Klapper W, Pott C, Unterhalt M, Dreyling MH (2020) Treatment of older patients with mantle cell lymphoma (MCL): long-term follow-up of the randomized European MCL elderly trial. J Clin Oncol 38(3):248–256. https://doi.org/10.1200/JCO.19.01294

Article  PubMed  Google Scholar 

Flinn IW, van der Jagt R, Kahl B, Wood P, Hawkins T, MacDonald D, Simpson D, Kolibaba K, Issa S, Chang J, Trotman J, Hallman D, Chen L, Burke JM (2019) First-line treatment of patients with indolent non-hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-Year follow-up study. J Clin Oncol 37(12):984–991. https://doi.org/10.1200/JCO.18.00605

Article  CAS  PubMed  PubMed Central  Google Scholar 

Soubeyran P, Gressin R (2016) Treatment of the elderly patient with mantle cell lymphoma. Hematol Am Soc Hematol Educ Program 2016(1):425–431. https://doi.org/10.1182/asheducation-2016.1.425

Article  Google Scholar 

Klapper W, Hoster E, Determann O, Oschlies I, van der Laak J, Berger F, Bernd HW, Cabecadas J, Campo E, Cogliatti S, Hansmann ML, Kluin PM, Kodet R, Krivolapov YA, Loddenkemper C, Stein H, Moller P, Barth TE, Muller-Hermelink K, Rosenwald A, Ott G, Pileri S, Ralfkiaer E, Rymkiewicz G, van Krieken JH, Wacker HH, Unterhalt M, Hiddemann W, Dreyling M, European MCLN (2009) Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network. J Hematop 2(2):103–111. https://doi.org/10.1007/s12308-009-0036-x

Article  PubMed  PubMed Central  Google Scholar 

Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32(27):3059–3068. https://doi.org/10.1200/JCO.2013.54.8800

Article  PubMed  PubMed Central  Google Scholar 

Meignan M, Gallamini A, Meignan M, Gallamini A, Haioun C (2009) Report on the First International Workshop on Interim-PET-Scan in Lymphoma. Leuk Lymphoma 50 (8):1257-1260. https://doi.org/10.1080/10428190903040048

McKay P, Leach M, Jackson B, Robinson S, Rule S (2018) Guideline for the management of mantle cell lymphoma. Br J Haematol 182(1):46–62. https://doi.org/10.1111/bjh.15283

Article  PubMed  Google Scholar 

Dreyling M, Campo E, Hermine O, Jerkeman M, Le Gouill S, Rule S, Shpilberg O, Walewski J, Ladetto M, Committee EG (2017) Newly diagnosed and relapsed mantle cell lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. https://doi.org/10.1093/annonc/mdx223

Article  PubMed  PubMed Central  Google Scholar 

Ratnasingam S, Casan J, Shortt J, Hawkes E, Gilbertson M, McQuilten Z, Grigoriadis G, Htun KT, Htet SM, Campbell P, Chai KL, Quach H, Patil S, Opat S (2019) Cytarabine-based induction immunochemotherapy in the front-line treatment of older patients with mantle cell lymphoma. Sci Rep 9(1):13544. https://doi.org/10.1038/s41598-019-49776-9

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grunhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balser C, Kaiser U, Weidmann E, Durk H, Ballo H, Stauch M, Roller F, Barth J, Hoelzer D, Hinke A, Brugger W (2013) Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381(9873):1203–1210. https://doi.org/10.1016/S0140-6736(12)61763-2

Article  CAS  PubMed  Google Scholar 

Raty R, Honkanen T, Jantunen E, Jyrkkio S, Karjalainen-Lindsberg ML, Kuittinen O, Lehto M, Mikkola M, Poikonen E, Rauhala A, Rimpilainen J, Rasanen A, Siitonen S, Suominen M, Vapaatalo M, Elonen E (2012) Prolonged immunochemotherapy with rituximab, cytarabine and fludarabine added to cyclophosphamide, doxorubicin, vincristine and prednisolone and followed by rituximab maintenance in untreated elderly patients with mantle cell lymphoma: a prospective study by the Finnish Lymphoma Group. Leuk Lymphoma 53(10):1920–1928. https://doi.org/10.3109/10428194.2012.672736

Article  CAS  PubMed  Google Scholar 

Wang ML, Jurczak W, Jerkeman M, Trotman J, Zinzani PL, Belada D, Boccomini C, Flinn IW, Giri P, Goy A, Hamlin PA, Hermine O, Hernandez-Rivas JA, Hong X, Kim SJ, Lewis D, Mishima Y, Ozcan M, Perini GF, Pocock C, Song Y, Spurgeon SE, Storring JM, Walewski J, Zhu J, Qin R, Henninger T, Deshpande S, Howes A, Le Gouill S, Dreyling M, Investigators S (2022) Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma. N Engl J Med 386(26):2482–2494. https://doi.org/10.1056/NEJMoa2201817

Article  CAS  PubMed  Google Scholar 

Jantunen E, Canals C, Attal M, Thomson K, Milpied N, Buzyn A, Ferrant A, Biron P, Crawley C, Schattenberg A, Luan JJ, Tilly H, Rio B, Wijermans PW, Dreger P, Sureda A (2012) Autologous stem-cell transplantation in patients with mantle cell lymphoma beyond 65 years of age: a study from the European Group for Blood and Marrow Transplantation (EBMT). Ann Oncol 23(1):166–171. https://doi.org/10.1093/annonc/mdr035

Article  CAS  PubMed  Google Scholar 

Martin P, Cohen JB, Wang M, Kumar A, Hill B, Villa D, Switchenko JM, Kahl B, Maddocks K, Grover NS, Qi K, Parisi L, Daly K, Zhu A, Salles G (2023) Treatment outcomes and roles of transplantation and maintenance rituximab in patients with previously untreated mantle cell lymphoma: results from large real-world cohorts. J Clin Oncol 41(3):541–554.